Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. It focuses on Fully Human Albumin Binding (FHAB) technology which utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2011 and is headquartered in Princeton, NJ.